157 related articles for article (PubMed ID: 38431830)
1. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 3: Alleviation of hypoxia, muscle-wasting, and modulation of redox functions in amyotrophic lateral sclerosis.
Li R; Han X; Wang Q; Wang C; Jing W; Zhang H; Wang J; Pan W
Int J Clin Pharmacol Ther; 2024 Apr; 62(4):169-177. PubMed ID: 38431830
[TBL] [Abstract][Full Text] [Related]
2. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 1: Biogenic components and identification of targets and signaling pathways in amyotrophic lateral sclerosis patients.
Lin J; Wang J; Wang C; Shan Y; Jing W; Fei Z; Pan W
Int J Clin Pharmacol Ther; 2024 Apr; 62(4):155-161. PubMed ID: 38239147
[TBL] [Abstract][Full Text] [Related]
3. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 2: Modulation of hypoxia, redox status, and mitochondrial protection in a neuroblastoma cell line, SH-SY5Y.
Yuan W; Lin J; Wang J; Wang C; Shan Y; Jing W; Fei Z; Pan W
Int J Clin Pharmacol Ther; 2024 Apr; 62(4):162-168. PubMed ID: 38431829
[TBL] [Abstract][Full Text] [Related]
4. Amyotrophic Lateral Sclerosis Symptom Score in Integrative Treatments (ALS-SSIT) for Evaluating Therapeutic Effect of Traditional Chinese Medicine: A Prospective Study.
Zheng X; Schröder J; Sima D; Wang M; Wang Q; Pan W
Comput Math Methods Med; 2022; 2022():7594481. PubMed ID: 35469217
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients.
Pirola A; De Mattia E; Lizio A; Sannicolò G; Carraro E; Rao F; Sansone V; Lunetta C
Clin Neurol Neurosurg; 2019 Sep; 184():105456. PubMed ID: 31382080
[TBL] [Abstract][Full Text] [Related]
8. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
[TBL] [Abstract][Full Text] [Related]
9. Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.
Mitsumoto H; Cheung K; Oskarsson B; Andrews HF; Jang GE; Andrews JA; Shah JS; Fernandes JA; McElhiney M; Santella RM
Trials; 2023 Jul; 24(1):449. PubMed ID: 37430314
[TBL] [Abstract][Full Text] [Related]
10. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
11. Creatine for amyotrophic lateral sclerosis/motor neuron disease.
Pastula DM; Moore DH; Bedlack RS
Cochrane Database Syst Rev; 2010 Jun; (6):CD005225. PubMed ID: 20556761
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of mecasin for treatment of amyotrophic lateral sclerosis: A phase IIa multicenter randomized double-blinded placebo-controlled trial.
Kim S; Yang M; Ku B; Cha E; Seo W; Son I; Kang H; Kim D; Song B; Yang CS; Kim S
J Ethnopharmacol; 2023 Oct; 315():116670. PubMed ID: 37257710
[TBL] [Abstract][Full Text] [Related]
14. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial.
Urbi B; Broadley S; Bedlack R; Russo E; Sabet A
BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
Oki R; Izumi Y; Fujita K; Miyamoto R; Nodera H; Sato Y; Sakaguchi S; Nokihara H; Kanai K; Tsunemi T; Hattori N; Hatanaka Y; Sonoo M; Atsuta N; Sobue G; Shimizu T; Shibuya K; Ikeda K; Kano O; Nishinaka K; Kojima Y; Oda M; Komai K; Kikuchi H; Kohara N; Urushitani M; Nakayama Y; Ito H; Nagai M; Nishiyama K; Kuzume D; Shimohama S; Shimohata T; Abe K; Ishihara T; Onodera O; Isose S; Araki N; Morita M; Noda K; Toda T; Maruyama H; Furuya H; Teramukai S; Kagimura T; Noma K; Yanagawa H; Kuwabara S; Kaji R;
JAMA Neurol; 2022 Jun; 79(6):575-583. PubMed ID: 35532908
[TBL] [Abstract][Full Text] [Related]
16. Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.
Diana A; Pillai R; Bongioanni P; O'Keeffe AG; Miller RG; Moore DH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006049. PubMed ID: 28067943
[TBL] [Abstract][Full Text] [Related]
17. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
18. Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].
Brooks BR; Heiman-Patterson T; Wiedau-Pazos M; Liu S; Zhang J; Apple S
PLoS One; 2022; 17(6):e0258614. PubMed ID: 35700157
[TBL] [Abstract][Full Text] [Related]
19. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
20. Slower progression of amyotrophic lateral sclerosis with external application of a Chinese herbal plaster-The randomized, placebo-controlled triple-blinded ALS-CHEPLA trial.
Schröder S; Wang M; Sima D; Schröder J; Zhu X; Zheng X; Liu L; Li T; Wang Q; Friedemann T; Liu T; Pan W
Front Neurol; 2022; 13():990802. PubMed ID: 36324375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
